GLP-1–based medications (such as semaglutide, known by brands including Ozempic and Wegovy) have reshaped conversations about obesity treatment. Recent coverage points to three big takeaways: these drugs don’t produce the same results for everyone, researchers are exploring potential benefits beyond weight loss (including addiction-related outcomes), and public health leaders caution that injections alone won’t address the obesity crisis.

1) Do GLP-1 weight-loss drugs work for everyone?

No. While many people lose meaningful weight, response varies widely. In real-world use and clinical research, some people experience substantial reductions in appetite and weight, while others see modest change or stop due to side effects, cost, access barriers, or difficulty staying on treatment long enough to benefit.

Why the response can differ

  • Biology and metabolism: Body weight is regulated by multiple systems (hormones, brain reward pathways, energy expenditure). GLP-1 drugs target some of these levers, but not all.
  • Dose and adherence: Many regimens require gradual dose increases to improve tolerability. If someone can’t reach or maintain an effective dose, results may be smaller.
  • Side effects: Nausea, constipation, diarrhea, and fatigue can limit use for some people.
  • Coexisting conditions and medications: Sleep apnea, depression, certain psychiatric medications, insulin resistance, and other factors can influence appetite and weight change.
  • Environment and habits: Food environment, stress, sleep, and physical activity still matter. Medication can reduce hunger, but it doesn’t automatically build new routines.

What “not working” can actually mean

It’s also important to define success. For some people, “working” may be improved blood sugar, blood pressure, mobility, or reduced cravings—even if the scale change is smaller than expected. For others, the drug may be effective initially but weight returns after stopping, which highlights that obesity is often a chronic condition requiring ongoing management.

2) Beyond weight loss: could these drugs affect addiction risk?

Emerging research and reporting suggest GLP-1 medications may influence reward and craving pathways, raising the possibility of benefits for some addiction-related outcomes. The basic idea: appetite and substance cravings share overlapping brain circuits, and GLP-1 signaling may dampen reward-driven urges in certain contexts.

However, this is still an evolving area. Even if early findings look promising, it does not mean these medications are proven treatments for addiction today. Large, well-controlled clinical trials and clear clinical guidelines are needed before anyone should view GLP-1 drugs as an “addiction medication.”

3) Why injections alone won’t solve the obesity crisis

Public health voices are warning that relying on “weight-loss jabs” as the primary solution is misguided. Medications can be powerful tools for individuals, but population-level obesity is driven by broad factors: ultra-processed food availability, marketing, socioeconomic inequalities, sedentary work patterns, sleep disruption, stress, and limited access to preventive care and supportive environments.

A practical way to reconcile both truths

  • At the individual level: GLP-1s can be life-changing for some people, especially those with obesity-related health risks.
  • At the systems level: Durable progress also requires prevention strategies—healthier food environments, effective school and workplace policies, urban design that supports activity, and equitable access to nutrition and healthcare.

4) The celebrity “too thin” discourse: what it gets right—and wrong

Celebrity weight-loss headlines can amplify unrealistic expectations and intensify stigma. Some commentary worries about a trend toward appearing “too thin,” which can be triggering for people with eating disorders and can distort public perception of what healthy change looks like.

What’s worth keeping in mind: health is not reliably measured by appearance alone. GLP-1 drugs may be medically appropriate for some and inappropriate for others. Treating thinness as the goal—rather than improved health markers and quality of life—can push people toward unsafe behaviors and unhelpful comparisons.

5) If you’re considering a GLP-1 medication, focus on these questions

  • What is the medical goal? Weight loss, diabetes control, cardiovascular risk reduction, mobility, or symptom improvement?
  • What’s the plan for side effects and nutrition? Appetite suppression can lead to inadequate protein/fiber intake without guidance.
  • How will muscle mass be protected? Strength training and sufficient protein help reduce lean-mass loss during weight reduction.
  • What is the long-term strategy? If the medication is stopped, what supports are in place to reduce weight regain?
  • Is this safe with my history? Discuss pancreatitis history, gallbladder issues, GI conditions, eating disorder history, and medication interactions.

Bottom line

GLP-1 weight-loss drugs can be highly effective—but not universally so, and not in a vacuum. The most realistic view is that they’re one tool in a broader chronic-care approach: medical assessment, nutrition quality, strength and activity, sleep, mental health support, and (at the societal level) healthier default environments. The hype becomes more useful when it’s paired with context and a plan.